Olema Pharmaceuticals Adds Pipeline Depth with New Clinical Data
Olema Pharmaceuticals (NASDAQ:OLMA) reported positive Phase 1 data for its KAT6 inhibitor, OP-3136, at the ASCO Annual Meeting. The drug was well-tolerated and showed anti-tumor activity across multiple solid tumor types. This development adds depth to Olema's pipeline as it awaits results from its key palazestrant trials in breast cancer.
Tickers: $OLMA
Topics: breast cancer KAT6 inhibitor Phase 1 data pipeline expansion